Initially, first‐generation TKIs achieved a 5‐year overall survival (OS) of 14.6% (95% CI 9.7–21.9) for stage III/stage IV EGFR‐mutant (EGFRm) NSCLC.9 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.